Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-40346527 · 1 trial · 1 indication
The DAS28 is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP, and an overall assessment of disease activity.
| Arm | Type | Description |
|---|---|---|
| JNJ-40346527 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| JNJ-40346527 | DRUG | Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily. |
| Placebo | DRUG | Form=capsule; route=oral use; twice daily. |
Inclusion Criteria: * Diagnosis of rheumatoid arthritis (RA) for at least 6 months prior to screening * Have been positive for, or are positive at screening for, either anti-cyclic citrullinated peptide (anti-CCP) antibody or rheumatoid factor (RF) in serum * Have active RA with at least 6 swollen ...
JNJ-40346527 is an investigational small molecule being studied for the treatment of rheumatoid arthritis. It is intended for patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy. The drug is in Phase 2 clinical development and is not yet approved by regulatory authorities.
JNJ-40346527 is a small molecule developed by Johnson & Johnson for rheumatoid arthritis. The specific molecular target of JNJ-40346527 is not disclosed in the available information. It is being evaluated in a Phase 2 clinical trial for its efficacy and safety in patients with active rheumatoid arthritis.
JNJ-40346527 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is currently in Phase 2 clinical development for the treatment of rheumatoid arthritis.
JNJ-40346527 is in Phase 2 clinical development. It is an investigational drug for rheumatoid arthritis and has not been approved by the FDA or any other regulatory agency. The drug is being studied in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy.
JNJ-40346527 has been studied in one completed Phase 2 clinical trial, identified as NCT01597739. This randomized, double-blind, placebo-controlled trial enrolled 96 patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy. The trial was conducted across multiple countries including Argentina, Bulgaria, Chile, Czechia, Hungary, Poland, Russia, Singapore, South Korea, and Ukraine.
JNJ-40346527 is the sole name provided for this investigational drug. No alternative names or aliases have been identified in the available information. The drug is being developed by Johnson & Johnson for the treatment of rheumatoid arthritis and is currently in Phase 2 clinical trials.